drugset / Trial / NCT00889226

Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia

NCT00889226

Phase 4 Completed 161 enrolled JW Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized, open label, dose titration study to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia

Timeline

Start
2008-04
Primary completion
2009-05
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 10 mg
Comparator Atorvastatin Small molecule 20 mg
Subject Pitavastatin Small molecule 2 mg
Subject Pitavastatin Small molecule 4 mg

Indications